Share on LinkedInShare on LinkedIn

ARTICLE · 19 OCTOBER 2020

Medtech Funding In Canada: Challenges And Opportunities

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

Canada is globally recognized for its innovative health care landscape, from its leading hospitals and research institutions to its leadership in the adoption of medtech...

CanadaCorporate/Commercial Law

Canada is globally recognized for its innovative health care landscape, from its leading hospitals and research institutions to its leadership in the adoption of medtech, such as AI-enabled digital health care solutions.

995866a.jpg

Medtech is becoming one of the fastest growing segments in Canada's health care and life sciences sectors, particularly as COVID-19 has created a greater need for technologies that transform how health care providers leverage patient data to enable better outcomes and options.

Despite the heightened interest in medtech from both public and private markets, medtech companies-and particularly founder-led, early-stage companies-can struggle to secure and maintain funding throughout their products' lengthy and highly regulated development life cycles. While there is no one-size-fits-all formula, some key considerations can help early-stage medtech companies navigate the uphill path to funding through product development, regulatory pathways, and

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from